Where is Relmada located?

Relmada is located in Blue Bell, United States .

Who is the current CEO of Relmada?

Sergio Traversa is the current CEO of Relmada.

How many employees does Relmada have?

Relmada has 14 employees as of Jun 30, 2022.

When was the latest funding round of Relmada?

Relmada's latest funding round was on Oct 08, 2019.

Where does Relmada rank among its competitors?

Relmada ranks 45 amongst 574 active competitors.

Who are the top competitors of Relmada?

Relmada's top competitors are Jazz Pharmaceuticals, Recursion and Biogen.

Relmada - 2025 Company Profile, Funding & Competitors

Company Details

Relmada Therapeutics is a clinical-stage, publicly-traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities for the treatment of chronic pain. Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse-resistant, sustained release dosage form of the opioid analgesic levorphanol.

Website
Social

Key Metrics

Founded Year

2007

Location

Blue Bell, United States

Stage

Public

Total Funding

in 9 rounds

Latest Funding Round

Investors

BioAdvance & 2 more

Ranked

45^th among

Employee Count

as on Jun 30, 2022

Similar Companies

Jazz Pharmaceuticals &

Exit Details

Public

Legal entities associated with Relmada

Relmada is associated with 2 legal entities given below:

Legal Entity Name	Date of incorporation	Revenue	Net Profit	Employee Count
	Feb 08, 2007	-	531	978
	Feb 08, 2007	-	833	511

Get your free copy of Relmada's company profile

Relmada has raised a total funding of $13M over 9 rounds. Its first funding round was on Jun 06, 2013.

Relmada has 3 institutional investors including BioAdvance, Ben Franklin Technology Partners and .

Here is the list of recent funding rounds of Relmada:

Date of funding	Funding Amount	Round Name	Post money valuation	Revenue multiple	Investors
Oct 08, 2019	$826K	Post IPO	6003411	7783093	-
Jun 2019	$8.43M	Post IPO	9035433	5847347	-
May 16, 2019	$3.41M	Post IPO	4083284	1950972	-

Access funding benchmarks and valuations. Sign up today!

View details of Relmada's funding rounds and investors

The founders of Relmada is . is the CEO of Relmada.

View details of Relmada's Founder profiles and Board Members

Relmada's employee count trend

Relmada has 14 employees as of Jun 22. The total employee count is 40.0% more than what it was in Jun 21. Here is Relmada's employee count trend over the years:

Uncover Relmada's growth story! Sign up today!

Top competitors of Relmada include Jazz Pharmaceuticals, Recursion and Biogen. Here is the list of Top 10 competitors of Relmada, ranked by 秘密研究所 score :

Overall Rank	Company Details	Short Description	Total Funding	Investors	秘密研究所 Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of therapeutics for cancer and neurological disorders	$265M	InterWest Partners, Investor Growth Capital听&补尘辫;听	85/100
2nd	Recursion 2013, United States, Public	R&D based company focused on manufacturing of drugs for multiple therapeutic areas	$452M	HTIF, Menlo Ventures听&补尘辫;听	81/100
3rd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Tekla Capital Management, Ridgeback Capital Management听&补尘辫;听	78/100
4th	Neurocrine 1992, San Diego (United States), Public	Developer of small molecule therapeutics for endocrine and CNS disorders	$10M	Venrock, HBM Healthcare Investments听&补尘辫;听	74/100
5th	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	Credit Suisse, Athyrium Capital Management听&补尘辫;听	74/100
6th	Harmony Biosciences 2017, Plymouth Meeting (United States), Public	Developer of therapeutics for rare neurological diseases	$345M	Aisling Capital, Vivo Capital听&补尘辫;听	74/100
7th	Biohaven Pharmaceutical 2014, New Haven (United States), Acquired	Developer of therapies targeting neurological and neuropsychiatric diseases	$84.1M	Aisling Capital, Venrock听&补尘辫;听	73/100
8th	AskBio 2001, Durham (United States), Acquired	Provider of gene and protein therapies to treat various diseases	$235M	TPG, Golden Valley Capital听&补尘辫;听	73/100
9th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of genetically engineered cell therapies for multiple disorders	$821M	CPP Investments, Omega Funds听&补尘辫;听	72/100
10th	4D Molecular Therapeutics 2013, Emeryville (United States), Public	Developer of gene therapeutics for genetic disorders	$187M	Ridgeback Capital Management, Perceptive Advisors听&补尘辫;听	72/100
45th	Relmada 2007, Blue Bell (United States), Public	Developing novel drug products for the treatment of multiple disease	$13M	Ben Franklin Technology Partners, BioAdvance听&补尘辫;听	55/100